ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
Anixa Biosciences Inc
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026
$2.61−0.06 (-2.25%)
Close on Oct 19, 2026
- Market cap
- $89.22M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.49 (−36.34%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jul 31, 2026
Valuation
- Market cap
- $89.22M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.17
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$10.38M
- EPS, diluted
- -$0.34
- Book value per share
- $0.42
- Diluted shares
- 34M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$10.98M
Net income
-$10.38M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months